Related Experiment Video
Updated: Jul 4, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents
Sumio Matzno1, Yuka Yamaguchi, Takeshi Akiyoshi
1School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, Japan. smatzno@mukogawa-u.ac.jp
Abstract:
The possibility of vitamin K3 (VK3) as an anticancer agent was assessed. VK3 dose-dependently diminished the cell viability (measured as esterase activity) with IC50 of 13.7 microM and Hill coefficient of 3.1 in Hep G2 cells. It also decreased the population of S phase and arrested cell cycle in the G2/M phase in a dose-dependent manner. G2/M arrest was regulated by the increment of cyclin A/cdk1 and cyclin A/cdk2 complex, and contrasting cyclin B/cdk1 complex decrease. Finally, combined application demonstrated that VK3 significantly enhanced the cytotoxicity of etoposide, a G2 phase-dependent anticancer agent, whereas it reduced the cytotoxic activity of irinotecan, a S phase-dependent agent. These findings suggest that VK3 induces G2/M arrest by inhibition of cyclin B/cdk1 complex formation, and is thus useful as an enhancer of G2 phase-dependent drugs in hepatic cancer chemotherapy.
Insights
Vitamin K3 (VK3) shows potential as an anticancer agent, effectively reducing liver cancer cell viability and inducing cell cycle arrest. VK3 enhances G2 phase-dependent chemotherapy drugs for liver cancer treatment.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) remains a significant global health challenge.
- Novel therapeutic strategies are needed to improve treatment outcomes for liver cancer.
- Vitamin K analogs are being investigated for their potential anticancer properties.
Purpose of the Study:
- To evaluate the anticancer potential of vitamin K3 (VK3) against Hep G2 liver cancer cells.
- To elucidate the cell cycle effects and molecular mechanisms of VK3.
- To assess VK3's synergistic or antagonistic effects with established chemotherapeutic agents.
Main Methods:
- Cell viability was assessed using esterase activity assays.
- Cell cycle progression was analyzed by flow cytometry.
- Key cell cycle regulatory proteins (cyclins and cyclin-dependent kinases) were investigated.
- Combined cytotoxicity assays were performed with etoposide and irinotecan.
Main Results:
- VK3 dose-dependently decreased Hep G2 cell viability with an IC50 of 13.7 microM.
- VK3 induced cell cycle arrest at the G2/M phase.
- VK3 modulated the activity of cyclin/cdk complexes, notably decreasing cyclin B/cdk1 formation.
- VK3 enhanced the cytotoxicity of etoposide (G2-phase specific) but reduced that of irinotecan (S-phase specific).
Conclusions:
- Vitamin K3 exhibits significant anticancer activity in Hep G2 cells.
- VK3 induces G2/M cell cycle arrest, potentially through inhibition of cyclin B/cdk1 complex formation.
- VK3 shows promise as an enhancer for G2 phase-dependent chemotherapy in liver cancer treatment.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists